Navigation Links
Nephros Engages Joseph S. Cervia, M.D. as Strategic Consultant
Date:11/21/2011

;are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that:

 

  • we may not be able to continue as a going concern;
  • we may not be able to obtain funding if and when needed or on terms favorable to us in order to continue operations;
  • we may not obtain appropriate or necessary regulatory approvals to achieve our business plan or effectively market our products including, without limitation, FDA approval of our HDF system;
  • products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
  • we may encounter problems with our suppliers and manufacturers;
  • we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
  • HDF therapy may not be accepted in the United States and/or our technology and products may not be accepted in current or future target markets, which could lead to failure to achieve market penetration of our products;
  • we may not be able to sell our ESRD therapy or water filtration products at competitive prices or profitably;
  • we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
  • we may not be able to achieve sales growth in Europe and Canada or expand into other key geographic markets.

More detailed information about us and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in our filings with the SEC, including our Annual Repo
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nephros Reports Third Quarter 2011 Financial Results
2. Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System
3. Nephros Reports Second Quarter 2011 Financial Results
4. Nephros Files 510(k) Application for Hemodiafiltration System
5. Nephros Receives 510k Approval to Market Additional Ultrafiltration Products
6. Nephros Reports First Quarter 2011 Financial Results
7. Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada
8. Nephros Reports 2010 Fourth Quarter and Full Year Financial Results
9. Nephros Announces Split Adjusted Trade Date
10. Nephros Announces Completion of Reverse Stock Split
11. Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... , CORALVILLE, Iowa, Dec. 16 ... Business Development agreement with Baker Consulting out of Walnut ... out of South Florida. Baker Consulting has been ... and assisting the company with its recently reported acquisition ...
... , SALT LAKE CITY, Dec. 16 ... "Company"), a medical device company engaged in the development and ... that Joe Pepper, PhD, has been appointed to the TechniScan ... "Joe has extensive experience running small to large medical devices ...
Cached Medicine Technology:Vivakor Signs Business Development Agreement With Baker Consulting 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... alleviate the suffering of shingles could move a step closer ... the go-ahead. A new shingles drug (FV-100), discovered ... of Pharmacy together with a virology group at the Rega ... due to complete Phase II of its clinical trials. ...
... ... 23, 2010 – Phybridge Inc. announced that it has joined the Cisco Developer Network ... has successfully completed interoperability testing with Cisco Unified Communications Manager, 7.1. , ... (PRWEB) March 23, 2010 -- ...
... ... survivors of the earthquake in Haiti. The Grand Canyon University community has donated more than ... on January 12, 2010. , ... Phoenix, AZ (PRWEB) March 23, 2010 -- Grand Canyon University,s Compassion and Generosity ...
... , COLLEYVILLE, Texas , March 23 E ... of the SS Choice No.7 STEALTH, which they originally designed for ... soldiers last summer and has been battle tested in Iraq ... comes in a matte black finish that is difficult to see ...
... , March 23 PSI Ambassador, actress and singer/songwriter ... and dozens of others who met with Members of Congress today ... which included a briefing to Congress, an attempt to form the ... Kerry , Congressman Jim McGovern and students from Oyster-Adams ...
... Yogi Bear’s ... pricing for the 2010 season! Plan an affordable and fun family vacation in North ... resort fees - just memories in the making at this family campground. , ... (PRWEB) March 23, 2010 -- Yogi ...
Cached Medicine News:Health News:Welsh shingles drug set for final hurdle 2Health News:Phybridge Inc. Joins the Cisco Developer Network and Completes Cisco Interoperability Verification Testing 2Health News:Grand Canyon University (GCU) Creates Special Relief Fund and Raises Money for Haiti Earthquake Survivors 2Health News:Combat E-Cigarette in Demand by Civilians 2Health News:Combat E-Cigarette in Demand by Civilians 3Health News:PSI Ambassador Mandy Moore Calls on Congress for Clean Water 2Health News:PSI Ambassador Mandy Moore Calls on Congress for Clean Water 3Health News:PSI Ambassador Mandy Moore Calls on Congress for Clean Water 4Health News:Announcing 2010 Stimulus Pricing on Adirondack Family Vacations 2Health News:Announcing 2010 Stimulus Pricing on Adirondack Family Vacations 3
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...
Revised Drug calibrator that replaces existing Drug calibrator - this product contains Lithium in addition to Digoxin, Phenobarbital, OPhenytoin, & Theophulline....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
Medicine Products: